BGSF reports Q1 2026 results on May 7 having lost a fifth of its value in a month — a stock down 20% heading into a print from a micro-cap staffing firm that consensus estimates see posting a net loss.
The price damage is sharp and recent. The stock closed at $5.08 on May 6, down 6.4% on the day and 8.5% on the week. That follows a 20% drop over the past month. The RSI sits at 34, close to oversold territory, suggesting sellers have been dominant and the stock has had little chance to stabilise. Despite the slide, the borrow market tells a notably calm story — short interest is only 0.5% of the free float, and the cost to borrow is just 0.58%. Availability is loose. There is no sign of a crowded short or any meaningful squeeze dynamic in the lending data.
The options picture adds a different wrinkle. The put/call ratio is essentially at zero today — near the bottom of its 52-week range — running well below its 20-day average of 0.05. That z-score of -1.2 suggests the options market is not positioned defensively at all into this print. Either traders see limited downside from here after the stock's recent fall, or the options market in this small-cap name is simply too thin to be read with confidence. BGSF's market cap is around $62 million, which keeps liquidity in the options market sparse and makes individual PCR readings noisy.
The fundamental picture heading in is weak. Estimates point to quarterly revenue of $21 million and a net loss of around $1.4 million, or -$0.12 per EPS. That would mark continued contraction in a staffing business that has been struggling amid softer labour market demand. Days-to-cover stands at 8.7, a relatively elevated reading that reflects thin trading volume more than any squeeze threat. The ORTEX short score of 33 sits in the lower half of the range — not a name that short sellers are particularly excited about, even with the price having fallen sharply.
Institutional ownership is fragmented, with 36 holders and no dominant block. Poplar Point Capital initiated a position of 592,296 shares at end-2025, making it the second-largest disclosed holder at 5.3%. Vanguard and Dimensional both added modestly in Q1 2026. The sole analyst coverage on record — Roth MKM's March 2025 target cut to $9 from $12, while keeping a Buy — is now more than a year old and significantly above where the stock trades today. Given the staleness of that data, it offers little forward guidance. The analyst return potential column flags 93% upside to the mean target, but that target is based on stale coverage; the number should be treated with caution.
The May 7 print will test whether the business is stabilising at these revenue levels, or whether the top-line erosion is still deepening — and whether any path back to profitability is visible in the guidance.
See the live data behind this article on ORTEX.
Open BGSF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
